Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive Story from MarketBeat.com These 3 Stocks Trade at Discounts the Market Won't Ignore ForeverBy Dan Schmidt. Published: 1/5/2026. 
At a Glance - The S&P 500 posted another gain above 15% in 2025, but the market is now approaching historically concerning valuation levels.
- When valuations are elevated, slowing earnings growth is harshly punished, and investors often turn to value stocks for safety.
- These three large-cap stocks all trade well below their industry-average P/E ratios, which could help protect against market volatility in 2026.
The S&P 500 closed out 2025 with a total return of roughly 18% — the third straight year above historical norms, but below the blockbuster 25% gains of 2023 and 2024. AI enthusiasm remains the dominant market theme heading into 2026, and familiar names like NVIDIA Corp. (NASDAQ: NVDA) and Alphabet Inc. (NASDAQ: GOOGL) were higher on the first trading day. If you've ridden the AI rally since the 2022 market bottom, you're likely sitting on sizable gains and may be considering diversification, especially with a tech-heavy allocation. The S&P 500 is entering the year trading around 26x forward earnings — well above its 20-year average of roughly 16x. When valuations are this elevated, investors become hungry for earnings growth, and high-multiple stocks can fall out of favor quickly if growth cools. If interest rates remain high, 2026 could be a year when value investing reasserts itself. Trump's Next Export Ban Could Reshape the Global Economy
It's not semiconductors, AI chips or quantum computers. But none of those technologies can exist without it. On January 19th, 2026, Trump is expected to ban exports of something every tech company desperately needs—forcing them all to relocate to U.S. soil. See what he's about to ban here… Below are three ways to de-risk a portfolio by allocating to companies that enter the new year undervalued and overlooked. Each firm trades at a meaningful discount to its industry peers, yet both fundamental and technical tailwinds suggest those discounts may not last. Comcast: Strong Balance Sheet and Sports Expansion Enhance Outlook The Comcast Corp. (NASDAQ: CMCSA) was one of the biggest casualties of cord-cutting, as customers shifted away from bundled cable packages toward streaming services. A "lost decade" is an investor's worst nightmare, and CMCSA is roughly five months from that milestone — trading at about the same price it did in May 2016. But cord-cutting fatigue appears to be setting in: streaming platforms are raising prices and entering costly carriage disputes with major networks. Meanwhile, Comcast has quietly built a solid balance sheet and diversified revenue streams. Its forward price-to-earnings (P/E) ratio of 6.84 sits well below the communications industry average (16.5) and far beneath major peers such as The Walt Disney Co. (NYSE: DIS) and AT&T Inc. (NYSE: T). 
Comcast's broadband business remains a steady, high-margin cash generator. While Connectivity and Platforms revenue was down 1.4% year over year in Q3 2025, EBITDA margins for the residential and business segments were strong at 37% and 56%, respectively. The advertising business should also get a lift in 2026 — NBCUniversal holds rights to Super Bowl LX, the FIFA World Cup and the Winter Olympics in Italy. The company produced $4.9 billion in free cash flow in Q3 and continues to support its roughly 4.4% dividend. Comcast's value story may be gaining recognition: the stock is up nearly 10% over the past 30 days, and several technical signals point to additional upside potential. Micron: An Essential AI Stock Trading at a Deep Discount How can a stock that delivered roughly a 200% gain in 2025 still look undervalued? Even after that run, Micron Technology Inc. (NASDAQ: MU) trades at about 29x earnings while the broader tech sector is nearer to 75x — making Micron inexpensive relative to its AI-facing peers. A P/E of 29 isn't a bargain versus the broader market, but it's attractive for a company reporting roughly 57% year-over-year revenue growth, 57% gross margins and repeatedly raising guidance. 
Memory businesses tend to be high-margin, and Micron management says it is struggling to keep pace with insatiable demand from data centers. The price chart shows a healthy uptrend with support along the 50-day simple moving average (SMA). That technical picture aligns with the TradeSmith Health indicator: MU shares are in the Green Zone, signaling a strong trend with normal pullbacks. Pfizer: Fueling Pipeline Innovation Through Acquisitions Shares of Pfizer Inc. (NYSE: PFE) have lagged as the COVID-19 era receded; the stock is down more than 30% over the past five years. Peers such as Eli Lilly and Co. (NYSE: LLY) have surged ahead thanks to obesity treatments like Mounjaro. Today, Pfizer trades near historical low valuations (about 8.4x forward earnings) and is cheaper than most large-cap peers in the pharmaceutical sector. Pfizer's acquisition of Seagen is beginning to lift the oncology division, adding more than $6 billion in revenue since the deal closed in 2023. 
Although Pfizer was slow to pivot into the growing obesity-drug market, it has been bolstering its pipeline by acquiring two smaller drugmakers with oral and injectable options. The market has largely discounted Pfizer's prospects in this space, which helps explain the valuation gap. Low expectations can create opportunity: the stock doesn't yet reflect successful penetration into the GLP‑1 market. Additionally, Pfizer remains an attractive defensive holding given its low valuation and history of dividend growth.
| 
